The Windsor Framework – what does it mean for life sciences?
For more than two years Northern Ireland has faced difficulties trading with the wider UK. The 2020 Northern Ireland Protocol established systems for trade in and out of Northern Ireland, but has led to a mass of practical difficulties both in the flow of goods across the Irish Sea, and legal compliance for businesses operating […]
For more than two years Northern Ireland has faced difficulties trading with the wider UK. The 2020 Northern Ireland Protocol established systems for trade in and out of Northern Ireland, but has led to a mass of practical difficulties both in the flow of goods across the Irish Sea, and legal compliance for businesses operating in the province. The new Windsor Framework will not please everyone. However, it offers solutions that, if implemented, promise to address many of these problems.
Points to note for the life sciences sector include:
- There will be a move away from the application of EU rules and authorisation requirements for medicines, so that UK law will apply in Northern Ireland and the UK regulator, the MHRA, will be responsible for approval of medicines for the Northern Ireland market.
- The Falsified Medicines Directive will not apply in Northern Ireland.
- Northern Ireland business will still have access to the EU single market where their goods are compliant with EU law.
- Veterinary medicines remain to be addressed, although a grace period for goods from GB to flow into NI lasting until the end of 2025 is planned while a long-term solution is found.
Medical devices do not receive specific attention in the deal, suggesting that there will be no change to the current requirement to follow EU law in the Northern Ireland market. This is disappointing – the existing system is complex and difficult for suppliers to navigate. If the Windsor Framework goes well, however, there might be room for the addition of other product classes like medical devices to its scope.
Finally, unblocking of the Northern Ireland Protocol is expected to lead to progress in other areas. Important here is association to the Horizon Europe programme on scientific collaboration. Stalemate on this issue has been a source of frustration for UK researchers for a long time, and stop gap proposals, although welcome, are considered to fall short of what is needed for innovation to flourish. Hopes are now rising that a breakthrough will soon follow.
More in Science
Stephen Clarke: Leading the Way at the ATOM Festival of Science...
Stephen Clarke, our Principal at Cherwell College Oxford, is not only a distinguished leader and former British diplomat, but also a passionate advocate for science and education. As the Chairman of ATOM Festival of Science & Technology, Stephen plays a pivotal role in bringing world-class scientific discussions and innovations to the heart of Abingdon. Stephen’s leadership ensures that the festival remains dynamic, inclusive, and engaging for people of all ages.
Intertronics: Driving Innovation in Adhesives and Assembly Solutions
For over four decades, Intertronics has been at the forefront of providing high-performance adhesives, coatings, sealants, and application equipment to industries that demand precision and reliability. From electronics and medical devices to automotive and aerospace, Intertronics’ expertise ensures that manufacturers can optimise their bonding and assembly processes with cutting-edge solutions.
Owen Mumford: 70 Years of Innovation in Healthcare
Owen Mumford has been at the forefront of medical device innovation for over 70 years, pioneering solutions that enhance patient care and improve healthcare outcomes worldwide. Established in 1952 by Ivan Owen and John Mumford, the company has grown into a global leader in medical device design and manufacturing, with a commitment to quality, sustainability, and patient-centred innovation.
From this author
Mills & Reeve announces record turnover of £181m as new head...
Leading UK law firm Mills & Reeve has announced turnover growth of £13 million over the 2024/25 financial year, resulting in a new high annual turnover of £181 million. Its Oxford office has seen standout success, with 55% fee growth and a new head of office appointed to lead its next chapter.
Mills & Reeve advise VC fund on investment in AI cardio...
Our venture capital investment experts have advised on a $55 million Series C funding round for an Oxford-based pioneer of AI driven cardiology solutions.
Mills & Reeve building legal excellence in Oxford
Mills & Reeve is pleased to highlight the continued growth and success of its Oxford office, which has become a key part of the firm’s national presence since opening in 2022. The office has quickly established itself as a trusted legal partner to the region’s thriving business and innovation communities.


